Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		×
			NIOSH
			NIOSH

				All CDC
				Submit


The National Institute for Occupational Safety and Health (NIOSH)





Current Intelligence Bulletin 17: 2-Nitropropane						Print
																Related Pages
										April 25, 1977
DHHS (NIOSH) Publication Number 78-127
**Note:** This document is superseded by DHHS (NIOSH) Publication No. 80-142, OSHA/NIOSH Health Hazard Alert—2-Nitropropane (2-NP)
A recently completed inhalation study indicates that 2-nitropropane, a widely used solvent in industrial coatings and printing inks causes liver cancer in rats. In this study sponsored by the National Institute for Occupational Safety and Health (NIOSH), all laboratory rats exposed to C207 ppm 2-nitropropane over a six month period developed hepatocellular carcinoma or hepatic adenoma. Although this study suggests that 2-nitropropane is carcinogenic its carcinogenic potential in man has not yet been researched.
This Bulletin provides the results of this animal study along with other pertinent data, their implications for occupational healthy and precautions for handling 2-nitropropane in the workplace.

Background
Solvent systems containing 2-nitropropane are used in coatings (e.g., vinyl, epoxy, nitrocellulose, and chlorinated rubber), printing inks, and adhesives. Occupational exposure to these products may occur in various industries including industrial construction and maintenance, printing (rotogravure and flexographic inks), highway maintenance (traffic markings), shipbuilding and maintenance (marine coatings), furniture, food packaging and plastic products. NIOSH estimates that 100,000 workers are potentially exposed to Z-nitropropane in these and other industries.
Synonyms for 2-nitropropane include dimethylnitromethane, isonitropropane, nitroisopropane, and 2-NP. Trade names under which 2-nitropropane is marketed include NiPar S-20TM (commercial grade 2-nitropropane) and NiPar S-30TM (mixtures of 1- and 2-nitropropane). 2-Nitropropane (in concentrations ranging from approximately 5 to 25 percent) is used in a number of solvent systems to contribute desirable properties such as improved drying time, more complete solvent release, better flow and film integrity, retardation of blushing, greater wetting ability, improved electrostatic spraying, and increased pigment dispersion.
The sole known domestic producer of 2-nitropropane has been Commercial Solvents Corporation (recently acquired by International Minerals and Chemical Corporation, IMC). 2-Nitropropane has been manufactured at their Sterlington, Louisiana plant since 1955, and in a pilot plant in Peoria, Illinois from 1940 to 1955. Of the estimated thirty million pounds of Z-nitropropane produced annually, twelve million pounds per year are sold domestically; the remainder is either used internally at IMC or exported.

Toxicology
In an inhalation study conducted by Huntingdon Research Center under a NIOSH contract (HEW/NIOSH Project No. 210-75-0039), Sprague-Dawley male rats and New Zealand White male rabbits were exposed to commercial grade 2-nitropropane for seven hours per day, five days per week. One group of fifty rats and fifteen rabbits was exposed to 207 ppm 2-nitropropane; a second group of the same size was exposed to 27 ppm, while a third group was maintained as a control. Ten rats from each group were killed after exposure periods of two days, ten days, one month, three months, and six months. Liver neoplasms, described as hepatocellular carcinoma or hepatic adenoma, were observed in all ten rats killed after six months of exposure to 207 ppm 2-nitropropane. No tumors were observed in any other animals in this study, including controls. However, hepatocellular hypertrophy, hyperplasia, and necrosis were reported in rats exposed to 207 ppm 2-nitropropane for three months. In addition elevated liver weights were found in rats exposed to 207 ppm 2-nitropropane for one, three, and six months. Liver histopathology, as well as the liver weights, of rats exposed to 27 ppm 2-nitropropane did not differ from controls.
Although certain shortcomings do exist in the conduct of this study,* the experiment is sufficient to merit the concern of the occupational health community. NIOSH has been advised that further investigation of the toxicity of 2-nitropropane has recently begun (April, 1977) under the sponsorship of the IMC Chemical Group, Inc.
The effects of 2-nitropropane inhalation in laboratory animals have also been studied by Treon and Dutra (Arch. Ind. Hyg. and Occ. Med., 5: 52, 1952). Five species of laboratory animals (2 animals of each species per exposure level) were exposed to various concentrations of 2-nitropropane. Acute exposures ranged up to 9000 ppm for short time periods (as low as one hour), while chronic exposure levels ranged down to 83 ppm 2-nitropropane for as long as 26 weeks. Treon and Dutra reported no histologic changes in the monkeys, rabbits, guinea pigs and rats exposed to 328 ppm or less regardless of exposure time. ** However, both cats died within 17 days of exposure to 328 ppm and had severe liver damage and slight to moderate damage to the kidney and heart.
There are a number of published reports concerning acute health effects of occupational exposure to 2-nitropropane. One report of two workers attributes the death of one and liver damage in both workers to high level exposure to 2-nitropropane while painting the inside of a tank (Gaultier, M., *et al.*, Arch. d. Mal. Prof. 25: 425, 1964). Another paper relates that continual exposure to concentrations of 20 to 45 ppm 2-nitropropane caused workers in one plant to experience nausea, vomiting diarrhea anorexia, and severe headaches (Skinner, J.B., Ind. Med. 16: 441, 1947). A third report indicates that workers exposed to from 165 to 445 ppm mixed 1-and 2- nitropropane also experienced nausea, dizziness, headaches and diarrhea (Documentation of Threshold Limit Values, American Conference of Governmental Industrial Hygienists, 1971). In addition Williams, *et. al.*, (New Eng. J. of Med., 291: 1256, 1974) reported an excess of toxic hepatitis among construction workers applying epoxy resins to the walls of a nuclear power plant. Although the hepatitis in this case was attributed to exposure to a known hepatotoxin, p,p’-methylenedianiline 4,4′-diaminodiphenylmethane), these men were also observed to have used 2-nitropropane to remove the hardened resin from their skin.

NIOSH Action and Recommendation
In order to characterize the potential for exposure to 2-nitropropane in the work environment, the National Institute for Occupational Safety and Health plans to conduct industrial hygiene surveys at facilities where 2-nitropropane is manufactured or consumed. In addition, an attempt will be made to identify a suitable worker population for epidemiologic studies.
The current Occupational Safety and Health Administration (OSHA) standard for occupational exposure to 2-nitropropane is 25 ppm. However, in light of the new information generated by the Huntingdon study, and while the carcinogenic potential of 2-nitropropane is being further evaluated NIOSH believes that it would be prudent to handle 2-nitropropane in the workplace as if it were a human carcinogen. The attached interim recommended industrial hygiene practices were developed by NIOSH to help reduce occupational exposure to 2-nitropropane.
*[signature]*
John F. Finklea, M.D.
Director
Industrial Hygiene Practices to Reduce Exposure to 2-Nitropropane
The following are suggested good industrial hygiene practices that can help to reduce exposure to 2-nitropropane. The recent finding of liver cancer in laboratory rats exposed by inhalation to 207 ppm 2-nitropropane for six months has indicated a need to reduce worker exposure.
**Regulated Area:** Regulated areas should be established during manufacture filling operations, use, release, handling or storage.
**Access.** Access should be restricted to employees who have been properly informed of the potential hazard of 2-nitropropane exposure and proper control measures.
**Engineering Controls.** most effective control of any contaminant is control at the source of generation wherever possible. Effective engineering measures may include the use of walk-in hoods, or specific local exhaust ventilation. Suitable collectors should be used to prevent community air pollution.
Due to the explosive potential of 2-nitropropane, spark proof ventilation systems should be selected.
Wherever possible the operations utilizing 2-nitropropane should be enclosed (with appropriate ventilation) to reduce exposures to the operators and others in the area.**Respirators.** respiratory protective devices should only be used as an interim measure while engineering controls are being installed, for non-routine use and during emergencies. Considering the carcinogenic potential of 2-nitropropane and the current Occupational Safety and Health Administration (OSHA) standard based on other toxicity, the appropriate personal respiratory protective measure is the use of a positive pressure supplied air respiratory or a positive pressure self-contained breathing apparatus.
**Protective Clothing.** full body clothing should be provided and its use required for employees entering the regulated area. Upon exiting from the regulated area, the protective clothing should be left at the point of exit. With the last exit of the day, the protective clothing should be placed in a suitably marked and closed container for disposal or laundering. (Laundry personnel should be made aware of the potential hazard from handling contaminated clothing.)
**Cleanliness.** should be required to wash all exposed areas of the body upon exiting from the regulated area.
**Isolation.** operations involving 2-nitropropane should be placed in an isolated area, in combination with other engineering controls to reduce exposure to employees not directly concerned with the operations.
**Medical Monitoring.** employees with a potential exposure to 2-nitropropane should be placed under a medical monitoring program including history and medical examinations with specific emphasis on liver function tests.
**Substitution.** substitution of a solvent that does not contain 2-nitropropane is another possible control measure. Caution should be exercised in selecting a substitute for 2-nitropropane, giving full consideration to the possible toxic effects of the substitute.
Notes
* The fifty rats exposed to 207 ppm 2-nitropropane were weanling rats (younger and smaller than the other exposed rats and the control group) which were introduced to replace rats experiencing excess mortality during the first few days of exposure to 400 ppm 2-nitropropane. In addition, throughout the entire study, exposure to 2-nitropropane was conducted while food and water were present, thus introducing the potential for exposure by the oral route. [return to text]
** On subsequent examination by a NIOSH pathologist in March 1977, liver sections from two rats in this study which were exposed to about 300 ppm 2-nitropropane for seventeen exposures (7 hours each) showed clear cell foci. These and similar lesions are frequently seen prior to the development of hepatocellular carcinoma in rats exposed to known hepatic carcinogens. The lesions observed in the Treon and Dutra study are similar to those found in the liver sections of the rats in the Huntingdon study which were sacrificed after three months exposure to 207 ppm 2-nitropropane. [return to text]
							
					
							Last Reviewed:  June 6, 2014						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Error processing SSI file  Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue